한글목차

세계 바이오의약품 시장 규모는 2024년 4,992억 달러에서 2029년 7,945억 달러로 확대될 것으로 예상되며, 2024년부터 2029년까지 9.7%의 CAGR을 기록할 것으로 예측됩니다.

북미 바이오의약품 시장 규모는 2024년 2,472억 달러에서 2029년 3,973억 달러로 확대될 것으로 예상되며, 같은 기간 CAGR은 10.0%로 추정됩니다.

아시아태평양의 바이오의약품 시장 규모는 2024년 884억 달러에서 2029년 1,524억 달러로 확대될 것으로 예상되며, 같은 기간 동안 11.5%의 CAGR을 기록할 것으로 예측됩니다. .

세계의 바이오의약품 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규제 환경, 신흥 기술 및 기술 개발 동향, 시장 규모 추정과 예측, 각종 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약
• 개요
• 현재 시장 시나리오
• 부문 분석
• 기술의 진보
• 결론

제2장 시장 개요

• 개요
• 바이오의약품과 합성 의약품의 비교
• 바이오의약품 제조
• 바이오의약품 제조 공정
• 거시경제 요인 분석
• Porter's Five Forces 분석
• 공급망 분석
• 세포 및 유전자 치료 공급망

제3장 시장 역학

• 시장 역학
• 시장 성장 촉진요인
• 바이오의약품 수요 증가
• 바이오의약품에 대한 투자 증가
• 제품 개발 협업과 계약
• 맞춤형 의료로의 이동
• 고령화 진행과 만성질환 증가
• 시장 성장 억제요인
• 바이오시밀러의 출현
• 복잡한 제조 공정, 숙련된 전문가의 부족, 높은 생산 비용
• 시장 기회
• 신흥 국가의 바이오의약품 수요 증가
• 바이오의약품의 기술 혁신

제4장 규제 상황

• 미국의 승인 프로세스
• EU의 승인 프로세스
• 아시아태평양의 승인 프로세스

제5장 신기술과 개발

• 신기술
• 단클론항체의 진보
• 항체약물접합체
• 이중특이성 항체
• 나노바디
• 단쇄 가변 프래그먼트 항체
• 항체 모방체
• 항체 융합 단백질
• 백신의 진보
• 세포 및 유전자 치료의 진보

제6장 시장 세분화 분석

• 개요
• 세분화 내역
• 시장 분석 : 제품 유형별
• 단클론항체
• 백신
• 펩타이드 호르몬
• 세포 및 유전자 치료
• 기타
• 시장 분석 : 유래별
• 포유류
• 미생물
• 기타
• 시장 분석 : 용도별
• 종양
• 자가면역질환
• 감염증
• 기타
• 지역적 내역
• 시장 분석 : 지역별
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제7장 경쟁 정보

• 개요
• 가장 많이 팔리는 바이오의약품
• 시장 점유율 분석
• 단클론항체
• 백신
• 펩타이드 호르몬
• 세포 및 유전자 치료
• 전략적 대처
• 협정, 협력, 파트너십
• 인수
• 기타 전략

제8장 바이오의약품 시장의 지속가능성 : ESG 관점

• ESG : 소개
• 지속가능성 동향과 대처
• 환경
• 사회와 거버넌스의 대처
• ESG 리스크 평가
• 결론

제9장 부록

• 조사 방법
• 신흥 스타트업 기업/시장 디스럽터
• 정보 출처
• 약어
• 기업 개요
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• ELI LILLY AND CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• MERCK & CO. INC.
• NOVARTIS AG
• NOVO NORDISK A/S
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI

영문목차

The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.

The North American market for biologic therapeutic drugs is estimated to increase from $247.2 billion in 2024 to reach $397.3 billion by 2029, at a CAGR of 10.0% from 2024 through 2029.

The Asia-Pacific market for biologic therapeutic drugs is estimated to increase from $88.4 billion in 2024 to reach $152.4 billion by 2029, at a CAGR of 11.5% from 2024 through 2029.

Report Scope

This report provides an overview of the global biologic therapeutic drug market and analyzes market trends. It includes global revenue ($U.S. millions) for base year data for 2023 and estimated data for 2024. The forecast period is 2024 through 2029. The market is segmented based on product type, application, source and region. By product, the market is segmented into monoclonal antibodies, vaccines, peptide hormones, cell and gene therapies and others. By source, it is segmented into mammalian, microbial and others. By application, the market is segmented into oncology, autoimmune diseases, infectious diseases and others. The regions covered in this study are North America, Europe, Asia-Pacific, Middle East and Africa, and South America, focusing on the major countries in these regions. The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, South Korea and the Rest of Asia-Pacific.

The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking and share of key players in the global biologic therapeutic drug market. It also has a section dedicated to company profiles that covers such details as overview, key financials, product portfolio and recent developments of key market players.

Report Includes

• 49 data tables and 58 additional tables
• An overview of the current and future global markets for biologic therapeutic drugs and technologies
• An analysis of the global market trends, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
• Estimates of the size and revenue prospects of the global market, along with a market share analysis by product type, application, source and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, and the impact of macroeconomic factors
• Evaluation of the ongoing clinical trials and R&D activity for biologics production
• A look at the key drugs on the market and recent approvals, sales statistics and past performance of the top-selling biologics
• An analysis of patents, emerging trends and other developments in the industry
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Company profiles of major players within the industry, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Pfizer Inc., and Bristol-Myers Squibb Co.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Technological Advances
• Conclusion

Chapter 2 Market Overview

• Overview
• Biologic and Synthetic Drug Comparison
• Biologic Manufacturing
• Biopharmaceutical Manufacturing Process
• Macroeconomic Factors Analysis
• Porter's Five Forces Analysis
• Supply Chain Analysis
• Cell and Gene Therapy Supply Chain

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Growing Demand for Biologics
• Rising Investments in Biopharmaceuticals
• Product Development Collaborations and Agreements
• Transition Toward Personalized Medicines
• Rising Aging Population and the Growing Prevalence of Chronic Diseases
• Market Restraints
• Emergence of Biosimilars
• Complex Manufacturing, Lack of Skilled Professionals and High Production Costs
• Market Opportunities
• Rising Demand for Biopharmaceuticals in Emerging Countries
• Technological Innovations in Biologics

Chapter 4 Regulatory Landscape

• U.S. Approval Process
• European Union Approval Process
• Asia-Pacific Approval Process

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• Advances in Monoclonal Antibodies
• Antibody-Drug Conjugates
• Bispecific Antibodies
• Nanobodies
• Single-Chain Variable Fragments Antibodies
• Antibody Mimetics
• Antibody Fusion Proteins
• Advances in Vaccines
• Advances in Cell and Gene Therapies

Chapter 6 Market Segmentation Analysis

• Overview
• Segmentation Breakdown
• Market Analysis by Product Type
• Monoclonal Antibodies
• Vaccines
• Peptide Hormones
• Cell and Gene Therapy
• Others
• Market Analysis by Source Type
• Mammalian
• Microbial
• Others
• Market Analysis by Application
• Oncology
• Autoimmune Disease
• Infectious Diseases
• Others
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Overview
• Highest Selling Biologic Therapeutic Drugs
• Market Share Analysis
• Monoclonal Antibodies
• Vaccines
• Peptide Hormones
• Cell and Gene Therapy
• Strategic Initiatives
• Agreements, Collaborations and Partnerships
• Acquisitions
• Other Strategies

Chapter 8 Sustainability in Biologics Therapeutic Drug Market: An ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives
• Environmental
• Social and Governance Initiatives
• ESG Risk Ratings
• Concluding Remarks

Chapter 9 Appendix

• Research Methodology
• Emerging Start-ups/Market Disruptors
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• ELI LILLY AND CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• MERCK & CO. INC.
• NOVARTIS AG
• NOVO NORDISK A/S
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI